CStone CEO Boosts Stake to 4.87% in Sign of Long-Term Confidence

CStone Pharmaceuticals ( (HK:2616) ) has issued an announcement.

CStone Pharmaceuticals announced that its CEO, president of research and development, and executive director, Dr. Jianxin Yang, has further increased his personal stake in the company by purchasing 976,000 shares on the open market between November 2025 and January 2026, including 428,500 shares acquired over two days in late January 2026. Since taking over as CEO in August 2022, Dr. Yang has accumulated a total of 12,477,000 shares, bringing his holding to about 4.87% of the company’s issued share capital, which the board interprets as a strong signal of his confidence in CStone’s long-term investment value, operational resilience, and prospects for high-quality growth, and he has indicated he may further increase his shareholding when appropriate.

The most recent analyst rating on (HK:2616) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

More about CStone Pharmaceuticals

CStone Pharmaceuticals, listed on the Hong Kong Stock Exchange, is an innovation-driven biopharmaceutical company founded in 2015 that focuses on developing therapies in oncology, autoimmune/inflammatory conditions, and other key disease areas for patients in China and globally. The company has launched four innovative drugs, obtained approvals for 20 new drug applications across nine indications, and maintains a diversified pipeline of 16 candidates, including potentially first-in-class or best-in-class antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines, supported by an experienced management team covering the full drug development and commercialization spectrum.

Average Trading Volume: 9,286,217

Technical Sentiment Signal: Buy

Current Market Cap: HK$8.21B

Find detailed analytics on 2616 stock on TipRanks’ Stock Analysis page.